Cargando…
Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection
Despite the burden of disease of CVD and DM, there is a lack of experimentally validated literature exploring their association with exacerbation of COVID-19. Target receptors of medications commonly used to treat CVD and DM may be involved in the viral entry mechanism of SARS-CoV-2. We propose the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431108/ https://www.ncbi.nlm.nih.gov/pubmed/32838195 http://dx.doi.org/10.1007/s42399-020-00452-4 |
_version_ | 1783571529244606464 |
---|---|
author | Bangi, Shifa Barve, Rajas Qamar, Amna |
author_facet | Bangi, Shifa Barve, Rajas Qamar, Amna |
author_sort | Bangi, Shifa |
collection | PubMed |
description | Despite the burden of disease of CVD and DM, there is a lack of experimentally validated literature exploring their association with exacerbation of COVID-19. Target receptors of medications commonly used to treat CVD and DM may be involved in the viral entry mechanism of SARS-CoV-2. We propose the potential protective effects of these medications in COVID-19 infections, highlighting the need for further research. Firstly, AMPK mediated phosphorylation of ACE-2 by metformin as well as the drug’s alkaline properties may interrupt the natural disease progression. Secondly, DPP4 receptor involvement in the putative viral entry of SARS-CoV-2 may be prevented by DPP4i. Finally, recent studies have shown that statins’ ability to inhibit the cytokine storm may outweigh concerns of statin mediated ACE-2 upregulation in COVID-19. The complex interplay of factors affecting CVD and DM in COVID-19 patients makes the direct effects of medications difficult to examine. Therefore, further research is needed, in the context of SARS-CoV-2 and the molecular pathways it exploits, to potentially repurpose such pre-existing drugs for their use in COVID-19. |
format | Online Article Text |
id | pubmed-7431108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74311082020-08-18 Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection Bangi, Shifa Barve, Rajas Qamar, Amna SN Compr Clin Med Covid-19 Despite the burden of disease of CVD and DM, there is a lack of experimentally validated literature exploring their association with exacerbation of COVID-19. Target receptors of medications commonly used to treat CVD and DM may be involved in the viral entry mechanism of SARS-CoV-2. We propose the potential protective effects of these medications in COVID-19 infections, highlighting the need for further research. Firstly, AMPK mediated phosphorylation of ACE-2 by metformin as well as the drug’s alkaline properties may interrupt the natural disease progression. Secondly, DPP4 receptor involvement in the putative viral entry of SARS-CoV-2 may be prevented by DPP4i. Finally, recent studies have shown that statins’ ability to inhibit the cytokine storm may outweigh concerns of statin mediated ACE-2 upregulation in COVID-19. The complex interplay of factors affecting CVD and DM in COVID-19 patients makes the direct effects of medications difficult to examine. Therefore, further research is needed, in the context of SARS-CoV-2 and the molecular pathways it exploits, to potentially repurpose such pre-existing drugs for their use in COVID-19. Springer International Publishing 2020-08-17 2020 /pmc/articles/PMC7431108/ /pubmed/32838195 http://dx.doi.org/10.1007/s42399-020-00452-4 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Covid-19 Bangi, Shifa Barve, Rajas Qamar, Amna Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection |
title | Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection |
title_full | Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection |
title_fullStr | Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection |
title_full_unstemmed | Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection |
title_short | Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection |
title_sort | protective effects of cvd and dm medications in sars-cov-2 infection |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431108/ https://www.ncbi.nlm.nih.gov/pubmed/32838195 http://dx.doi.org/10.1007/s42399-020-00452-4 |
work_keys_str_mv | AT bangishifa protectiveeffectsofcvdanddmmedicationsinsarscov2infection AT barverajas protectiveeffectsofcvdanddmmedicationsinsarscov2infection AT qamaramna protectiveeffectsofcvdanddmmedicationsinsarscov2infection |